georgie18
3 years ago
SURF...$5.80...in the P/M...Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study ...:party:
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for GSK4381562 (formerly SRF813) to proceed into a first-in-human clinical trial. GSK4381562 is a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells.
In December 2020, Surface announced it had entered into an agreement in which GSK exclusively licensed worldwide development and commercial rights to GSK4381562. Surface will receive a $30 million milestone payment in conjunction with the initiation of the first Phase 1 study for GSK4381562 and is eligible to receive an additional $700 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales...
[7:43 AM]
georgie18 โ 11/04/2021
SURF...$7.73...Long Term Cup N Handle Continuation Pattern...with 45 Million range O/S...Target...$27...Break/Hold $18 range and you hit Blue Skies with NO Topside resistance...imo...we shall see... https://schrts.co/rGqEChPJ ...Long Hold for me...:party:
realfast95
3 years ago
Selected Anticipated Near-term Corporate Milestones:
SRF388 clinical data presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, to be held virtually June 4-8, 2021.
Webcast to provide data from ongoing SRF388 and SRF617 Phase 1 clinical studies, to be held on Friday, June 4, 2021 at 8:00 a.m. ET.
Investigational new drug (IND) filing for SRF813, partnered with GlaxoSmithKline, anticipated in 2021.
georgie18
3 years ago
SURF...$7.97...in the A/H...CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for one of the companyโs lead therapeutic candidates, SRF617, for the treatment of patients with pancreatic cancer.
โWe are pleased to receive this important designation from the FDA, which supports our conviction that new immunotherapies for pancreatic cancer are urgently needed,โ said Alison OโNeill, M.D., senior vice president, clinical development at Surface Oncology. โWe are very encouraged by our clinical progress to date with SRF617, a highly innovative therapy with the potential to promote anti-tumor immunity in patients with cancer. SRF617 is in Phase 1/1b studies across a variety of solid tumors, including combination studies with gemcitabine and abraxane in patients with pancreatic cancer.โ...:party:
instock58
3 years ago
SURF After Hours FDA News , " Surface Oncologyโs SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer "
News Out After Hours Tuesday
Up 19% AH on Very Heavy Volume.
https://finance.yahoo.com/news/surface-oncology-srf617-receives-orphan-203000832.html
Motley Fool Thur Evening..
https://www.fool.com/investing/2021/03/30/why-surface-oncology-is-flying-higher-after-hours/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
TradingView - Buy Rated Tech. Analysis
https://www.tradingview.com/symbols/NASDAQ-SURF/technicals/
Finviz
https://elite.finviz.com/quote.ashx?t=surf
68% Increase in message volume and Large Rise in sentiment,,,
https://stocktwits.com/symbol/SURF
Maybe Be A Very HOT Stock Premarket, before Reg Hours Volume smacks it even higher..
May The Force Be with You ......
May The Energy Be Yours.....
georgie18
4 years ago
SURF...$8.00 in the P/M...CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surfaceโs SRF388, an investigational antibody therapy targeting IL-27, with Merckโs KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1 study of SRF388 and will be evaluated in patients with solid tumors, with a focus on patients with liver cancer and kidney cancer.
โSurface is the only company with clinical-stage IL-27 research and we believe that this cytokine may play an important role in resistance to anti-PD-1 treatment,โ said Rob Ross, M.D., incoming chief executive officer at Surface Oncology. โThis collaboration with Merck will add an important dimension to the SRF388 clinical program and allow us to more rapidly assess its potential to deliver truly breakthrough therapies that can transform treatment for people with cancer.โ
Fress
4 years ago
Cathie Wood from ARKG literally bought a cool million SURF shares in one day a few weeks ago. She has the best financial research team & tools and is in close contact with SURF management. ARKG Cathie Wood now owns close to 10% of the shares and she has been Buying SURF shares almost every day.
Surface Oncology hires bankers to explore sale - StreetInsider
The company received a takeover approach from GlaxoSmithKline (GSK)
and has hired an investment bank, StreetInsider reports.
Surface Oncology wants bankers to look for any other possible M&A interest beyond GSK, StreetInsider says.
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html
FDA Fast tracks SRF388 (Surface Oncology), a fully human anti-interleukin-27 antibody, for treatment of patients with hepatocellular carcinoma
Cathie Wood from ARKG owns 10% and keeps adding shares. of the SURF float Eli Lily holds 8.5% through LLV ventures fund. Novartis just disclosed a roughly 10% stake after hours via Form SC 13G. institutions own 67% of the 40 million shares outstanding
Cash runway through 2023 ($102.5M in cash as of Sept 30th; received $85Million from GSK GlaxoSmithKline in December.
Two strategic partnerships (Novartis & GSK GlaxoSmithKline) validate strong IO drug discovery capabilities.
GSK GlaxoSmithKline Partnership SRF813
cumulative milestones up to $730 million
โข Tiered royalties on annual net sales
(high single-digit to mid-teens %
Novartis Partnership: NZV930
โข Upfront payment of $70M, total
cumulative milestones up to $525 million
โข Tiered royalties on annual net sales
(high single-digit to mid-teens %)
Detailed clinical update for both SRF617 & SRF388 to be presented in the first half of 2021.
SRF388 is the ONLY anti IL-27 targeted agent in clinical development. Shows antimetastatic tumour activity and increased the production of key inflammatory cytokines.
SRF388 is a blockbuster in the making, the Il-27 targeting antibody. There is compelling evidence clinically to understand IL-27s role in tumour types. This is the next one that will get huge partnership deal!!
Total = $1.2B Billion just for licence worldwide rights with Novartis & GSK plus double digit tiered royalties.
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer.
https://investors.surfaceoncology.com/news-releases/news-release-details/surface-oncology-announces-fda-fast-track-designation-granted-us
SURF has 4 other VERY promising targets. SRF617,SRF388, SRF114,SRF231 More partnership deals to come.
undervalued and the chart is bullish 1 year is amazing building & looking for continuation to the upside.
SURF Chart cup and handle on the weekly!!
https://stockcharts.com/h-sc/ui?s=SURF
Outstanding team of experienced company builders & oncology drug developers.
In the "Lightning Round" segment of Mad Money Friday night, Jim Cramer was bullish on Surface Oncology (SURF) , an immuno-onocolgy company developing next-generation antibody therapies.
https://realmoney.thestreet.com/investing/surface-oncology-is-set-for-further-gains-how-to-buy-it-15542979
SURF Feb 2021 Biz presentation:
https://investors.surfaceoncology.com/static-files/9a6d888d-dae2-419d-a0fc-c96058f9aa7c
Surf Website:
https://www.surfaceoncology.com/
Surf Pipeline & Programs:
https://www.surfaceoncology.com/pipeline-programs/
$SURF
Fress
4 years ago
Catalysts for 1st half of 2021: Filing of IND (investigational new drug) status for SRF813. Results for SRF617 and results for 388.
Surface Oncology hires bankers to explore sale - StreetInsider
Surface Oncology (SURF, +16%) is climbing sharply on a report that its exploring a sale.
The company received a takeover approach from GlaxoSmithKline (GSK)
and has hired an investment bank, StreetInsider reports.
Surface Oncology wants bankers to look for any other possible M&A interest beyond GSK, StreetInsider says.
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html
In the "Lightning Round" segment of Mad Money Friday night, Jim Cramer was bullish on Surface Oncology (SURF) , an immuno-onocolgy company developing next-generation antibody therapies.
https://realmoney.thestreet.com/investing/surface-oncology-is-set-for-further-gains-how-to-buy-it-15542979
Cathie Wood ARKG #1 wall street stock picker bought over a million SURF shares in one day a few weeks back she has doubled her position to over 4 million shares in the stock recently Cathie knows something!
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer.
https://investors.surfaceoncology.com/news-releases/news-release-details/surface-oncology-announces-fda-fast-track-designation-granted-us
SURF chart.
https://stockcharts.com/h-sc/ui?s=surf
Surface Oncology is a clinical-stage immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment.
SURF Partnership's with Novartis worth
$525M
(For SRF373)Partnership with GSK GlaxoSmithKline worth
$730M
(For SRF813)
Total = 1.15B just for licence worldwide rights.
Feb 2021 Biz presentation:
https://investors.surfaceoncology.com/static-files/9a6d888d-dae2-419d-a0fc-c96058f9aa7c
Surf Website:
https://www.surfaceoncology.com/
Surf Pipeline & Programs:
https://www.surfaceoncology.com/pipeline-programs/
$SURF
Fress
4 years ago
Cathie Wood from ARKG owns 10% and keeps adding shares. of the SURF float Eli Lily holds 8.5% through LLV ventures fund. institutions own 67% of the 40 million shares outstanding
Cash runway through 2023 ($102.5M in cash as of Sept 30th; received $85Million from GSK GlaxoSmithKline in December.
Two strategic partnerships (Novartis & GSK GlaxoSmithKline) validate strong IO drug discovery capabilities.
GSK GlaxoSmithKline Partnership SRF813
cumulative milestones up to $730 million
โข Tiered royalties on annual net sales
(high single-digit to mid-teens %
Novartis Partnership: NZV930
โข Upfront payment of $70M, total
cumulative milestones up to $525 million
โข Tiered royalties on annual net sales
(high single-digit to mid-teens %)
Detailed clinical update for both SRF617 & SRF388 to be presented in the first half of 2021.
SRF388 is the ONLY anti IL-27 targeted agent in late Pre clinical development. Shows antimetastatic tumour activity and increased the production of key inflammatory cytokines.
SRF388 is a blockbuster in the making, the Il-27 targeting antibody. There is compelling evidence clinically to understand IL-27s role in tumour types. This is the next one that will get huge partnership deal!! Canโt wait for phase 1 data.
Surf recap: Partnership with Novartis worth
$525M
(For SRF373)Partnership with GSK GlaxoSmithKline worth
$730M
(For SRF813)
Total = 1.15B just for licence worldwide rights.
SURF has 4 other VERY promising targets. SRF617,SRF388, SRF114,SRF231 More partnership deals to come.
undervalued and the chart is bullish 1 year is amazing building & looking for continuation to the upside.
https://stockcharts.com/h-sc/ui?s=SURF
Outstanding team of experienced company builders & oncology drug developers.
Feb 2021 Biz presentation:
https://investors.surfaceoncology.com/static-files/9a6d888d-dae2-419d-a0fc-c96058f9aa7c
Surf Website:
https://www.surfaceoncology.com/
Surf Pipeline & Programs:
https://www.surfaceoncology.com/pipeline-programs/
$SURF